<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="747">
  <stage>Registered</stage>
  <submitdate>16/09/2005</submitdate>
  <approvaldate>24/10/2005</approvaldate>
  <actrnumber>ACTRN12605000686606</actrnumber>
  <trial_identification>
    <studytitle>A randomised, controlled trial of two different algorithms for maintaining asthma control during down titration on long acting bronchodilators and inhaled corticosteroids (CRC P7S3)</studytitle>
    <scientifictitle>A randomised, controlled trial of two different algorithms for maintaining asthma control during down titration on long acting bronchodilators and inhaled corticosteroids</scientifictitle>
    <utrn />
    <trialacronym>CRC P7 S3</trialacronym>
    <secondaryid>CRC for Asthma</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This project is to assess the relative effectiveness of two clinically applicable algorithms to guide titration of ICS therapy in subjects with asthma. The effectiveness of the algorithm will be assessed in terms of its capacity to minimise long-term ICS (and oral steroid) usage while maintaining optimal asthma control (asthma-free days and quality of life).Down titration of ICS according to pre-set clinical criteria for well controlled asthma (usual care) or levels of exhaled nitric oxide (eNo).</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Asthma free days</outcome>
      <timepoint>Participants will visit the clinic to be evaluted every 2 months for 8 months.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Participants will visit the clinic to be evaluted every 2 months for 8 months.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Total exacerbations</outcome>
      <timepoint>Over 8 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean steroid dose (oral and inhaled)</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Asthma control questionnaire score</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinic FEV1</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean morning PEF</outcome>
      <timepoint>2 weeks before and after dose changes</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>AHR</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>eNo</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom score</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reliever use.</outcome>
      <timepoint>Measured every 2 months for 8 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Asthma must be well controlled over the two weeks prior to entry on ICS &gt; 100 mcgs fluticasone  or equivalent daily + LABA (salmeterol or formoterol), with medication dose stable for four weeks prior to entry. a.FEV1 criterion for well controlled asthma at entry:  FEV1 must be within 10% of the best within the last 2 years, and equal to or above 65% of predicted FEV1 b.Maximum reliever use must be 3 times weekly (excluding prophylactic use for exercise) at Visit 1.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>This will be achieved by the research assistant or investigator at each site providing the results of the assessment of control for both algorithms to a third person not directly involved in the study. This person will consult the randomisation code and a medical practitioner will submit a request to pharmacy for the appropriate study medication based on the subject's allocation.</concealment>
    <sequence>Computer software SAS-Randomized 1:1 within each site (4 sites) and the packs were randomly numbered in blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>CRC for Asthma</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Woolcock Institute of Medical Research</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>CRC for Asthma</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Woolcock Institute of Medical Research</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>John Hunter Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Christine Jenkins</name>
      <address>Woolcock Institute of Medical Research
PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95157928</phone>
      <fax>+61 2 95505865</fax>
      <email>crj@woolcock.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Wendy Taylor</name>
      <address>Woolcock Institute of Medical Research
PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505065</fax>
      <email>volunteers@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>